Ocugen (OCGN) announced that the Data and Safety Monitoring Board, or DSMB, for the OCU410 ArMaDa clinical trial recently convened and approved continuation of the second phase of the Phase 1/2 study.
Phase 1/2 study of the HER3-directed antibody-drug conjugate patritumab deruxtecan (MK-1022) as monotherapy in patients with gastrointestinal cancers. This is an ASCO Meeting Abstract from the 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results